Core Viewpoint - The company, Weili Medical (603309.SH), has received notification from the EU announcement agency regarding the addition of multiple products to its EU Medical Device Regulation (MDR) certification, indicating compliance with the latest EU medical device regulations and enabling legal sales in relevant overseas markets [1] Group 1 - The company has obtained EU MDR certification for several products, which signifies adherence to the latest EU medical device regulatory requirements [1] - The new certification allows the company to meet the latest market access conditions in the EU, facilitating the promotion and sales of its products in corresponding markets [1]

Core Viewpoint - The company has recently obtained multiple EU Medical Device Regulation (MDR) certifications for various products, indicating compliance with EU regulations and market access, which will facilitate product promotion and sales, although the specific impact on future performance cannot be predicted [1] Group 1 - The company received EU MDR certification for several products, including Class I sterilized catheter care kits, Class IIa micro-mesh nebulizers (consumables), and Class IIb catheter bags [1] - The certifying body for these products is TÜV SÜD Product Service GmbH, with certification issuance dates primarily on February 3, 2026, and expiration dates in 2028 [1] - Obtaining these certifications demonstrates that the products meet EU regulatory requirements, which is beneficial for market entry [1]

Core Viewpoint - The "Shengong-Hua Tuo" brain-controlled acupuncture and neuro-rehabilitation equipment platform has been launched in Tianjin, marking a significant advancement in integrating traditional Chinese medicine with cutting-edge brain-computer interface technology [1][2]. Group 1: Technology and Innovation - The platform targets patients with neurological disorders such as stroke-induced paralysis, utilizing a combination of brain-computer interface (BCI) and smart wearable acupuncture technology [1]. - Three core technologies have been developed: "Active Acupuncture," "Quantitative Acupuncture," and "Integrated Acupuncture," addressing key challenges in traditional acupuncture practices [2]. - The "Active Acupuncture" technology enhances patient engagement by allowing the brain to actively participate in the acupuncture process [2]. - "Quantitative Acupuncture" provides real-time evaluation of acupuncture effects, optimizing the treatment feedback loop [2]. - "Integrated Acupuncture" creates a sensory-motor coupling rehabilitation system by accurately detecting brain activity in sensory and motor areas [2]. Group 2: Research and Development - The research team has been focused on modernizing traditional Chinese medicine techniques and integrating them with advanced technologies like brain-computer interfaces [3]. - Previous projects include the development of a portable transcutaneous electrical stimulation device, which has been used in space missions to ensure astronaut health [3]. - Future plans involve the continued development of brain-controlled acupuncture and massage equipment, contributing to the evolution of "smart traditional Chinese medicine" [3].

Group 1 - The article discusses the performance and characteristics of various ETFs tracking the STAR Market indices, highlighting their focus on high-tech sectors such as semiconductors, medical devices, and software development [2][3] - The STAR 50 ETF tracks the STAR 50 Index, which consists of 50 stocks with large market capitalization and good liquidity, with over 65% of its composition in semiconductors and nearly 80% in hard technology sectors [2] - The STAR 100 ETF focuses on 100 medium-cap stocks, with over 75% of its composition in electronics, power equipment, and pharmaceutical industries [2] - The STAR 200 ETF targets 200 small-cap stocks, emphasizing growth potential, with significant representation from electronics, biomedical, and machinery sectors [2] - The STAR Composite Index ETF covers all market segments and focuses on core industries such as artificial intelligence, semiconductors, and innovative pharmaceuticals, encompassing all 17 primary industries listed on the STAR Market [3] - The STAR Growth ETF includes 50 stocks with high growth rates in revenue and net profit, with over 65% of its composition in the electronics and communications sectors [3] Group 2 - As of the midday close on February 4, 2026, the STAR 50 Index showed a decline, while the STAR 100 Index had a rolling P/E ratio of 213.8 times, and the STAR 200 Index had a rolling P/E ratio of 167.4 times [2] - The STAR Composite Index had a rolling P/E ratio of 223.3 times, and the STAR Growth Index had a rolling P/E ratio of 193.2 times, indicating varying levels of valuation across these indices [3] - The article notes that the STAR Market indices have been established at different times, with the STAR 50 Index launched on July 23, 2020, the STAR 100 Index on August 7, 2023, the STAR 200 Index on August 20, 2024, and the STAR Composite Index on November 4, 2022 [3]

观点网讯：近日，脑机交互与人机共融海河实验室宣布，由周鹏智慧中医团队牵头，联合天津中医药大 学第一附属医院、滨海新区中医医院、天津中医药大学及天中依脉公司共同研发的全国首个脑控针灸融 合神经康复装备平台"神工-华佗"正式落地。 该平台集成"脑机接口+智能穿戴式针灸"技术，可将患者脑电信号实时转化为精准穴位电刺激参数，实 现个体化康复干预。项目曾获国家载人航天实验专项支持，其前身"便携式经皮穴位电刺激装置"已随多 艘神舟载人飞船完成太空验证，为中医智能化装备在天基环境下的应用奠定基础。 免责声明：本文内容与数据由观点根据公开信息整理，不构成投资建议，使用前请核实。 ...

Core Viewpoint - Medtronic plans to exercise its acquisition option for CathWorks, a private company specializing in coronary physiological assessment technology, with a total consideration of up to $585 million (approximately 4.1 billion RMB) [2] Group 1: Acquisition Details - The acquisition is expected to be completed before the end of Medtronic's fiscal year 2026, pending review by the U.S. Federal Trade Commission (FTC) [2] - This move follows a strategic partnership established in 2022 between Medtronic and CathWorks to promote the FFRangio system in the U.S., Europe, and Japan [3] Group 2: Technology and Product Path - The acquisition signifies Medtronic's commitment to the coronary physiological assessment technology route [4] - CathWorks' FFRangio system generates FFR value distribution across the entire coronary tree based on standard coronary angiography images, utilizing AI and computational fluid dynamics without the need for pressure wires or drug stimulation [9] Group 3: Decision Support Capabilities - FFRangio has evolved beyond a diagnostic tool to become a real-time decision support layer in interventional procedures, aligning with Medtronic's focus on data-driven and integrated processes in interventional fields [11][13] - The technology provides real-time data to support personalized treatment strategies and has the potential to reshape the workflow in catheterization labs [16] Group 4: Strategic Implications - The acquisition indicates a shift in the competitive focus of coronary interventions from "device itself" to "decision efficiency" [17] - The integration of imaging, AI, and physiological assessment is moving towards a unified platform, enhancing the value of tools embedded in the complete interventional process [17] - Large platform companies prefer to accelerate the acquisition of key capabilities through mergers rather than internal development [18] Group 5: Financial Impact - The acquisition is expected to have a negligible impact on Medtronic's GAAP and adjusted EPS for fiscal year 2027, with potential neutral to positive contributions in the medium to long term [19] - Prior to the completion of the transaction, Medtronic and CathWorks will continue to operate independently, allowing for further integration of products, channels, and teams [20] Group 6: Industry Trends - The acquisition reflects a trend in mature interventional fields where innovation is shifting towards reducing hesitation and increasing certainty in decision-making [21] - Companies that can simplify complex judgments and seamlessly integrate into physicians' daily workflows are likely to gain a competitive advantage in the next phase [22] - CathWorks provides Medtronic with a ready-made solution to address these challenges [23]

Core Viewpoint - The article highlights the launch of China's first brain-controlled acupuncture and neuro-rehabilitation equipment platform, "Shengong-Hua Tuo," developed by a collaborative team led by the Brain-Computer Interaction and Human-Machine Integration Haihe Laboratory [1]. Group 1 - The innovative technology combines "brain-computer interface + smart wearable acupuncture," supported by multiple preliminary projects, including the national manned spaceflight experimental project [2]. - The research team has focused on the modernization of traditional Chinese medicine (TCM) technologies and the integration of cutting-edge technologies like brain-computer interfaces for several years [2]. - A previous collaboration between Tianjin University and Tianjin University of Traditional Chinese Medicine resulted in the development of a "portable transcutaneous acupoint electrical stimulation device (space acupuncture)," which has been tested in space aboard several Shenzhou series manned spacecraft, marking a pioneering application of TCM smart acupuncture equipment in space [3].

Company and Industry Summary Company Overview - The company, Guichuang Tongqiao, is a leading domestic player in the neuro-interventional and peripheral intervention sectors, actively expanding into overseas markets [1] Financial Performance - The company forecasts a revenue exceeding 1.05 billion yuan for the year 2025, representing a year-on-year growth of approximately 34.6% [1] - The projected net profit for 2025 is over 240 million yuan, with a year-on-year increase of about 139.4% [1] - By 2025, the company expects its overseas market revenue to grow by more than 100% [1] Strategic Initiatives - The company announced a strategic acquisition of the German company Optimed in January 2026, aimed at enhancing its presence in the European and global markets [1] - This acquisition is expected to accelerate the promotion and implementation of innovative products in international markets, leveraging synergies between production bases in China and Germany [1] Financial Resources - As of the first half of 2025, the company has available financial resources totaling 2.53 billion yuan, indicating a strong liquidity position [2] - The company plans to continue seeking opportunities for external mergers and acquisitions and overseas business development to solidify its leading position in the industry [2] Long-term Outlook - The company is entering a phase of rapid profit release, with significant scale effects as sales continue to grow [3] - Over the next three years, revenue is expected to grow significantly, with forecasts of 1.388 billion yuan and 1.805 billion yuan for 2026 and 2027, respectively, reflecting year-on-year growth rates of 30.8% and 30.1% [3] - Projected net profits for 2026 and 2027 are estimated at 320 million yuan and 418 million yuan, with year-on-year growth of 32.9% and 30.8% [3] - The company maintains a "buy" rating with projected price-to-earnings ratios of 24 and 18 for 2026 and 2027, respectively [3]

Group 1 - The core viewpoint of the article is that Blue Sail Medical has reported a positive turnaround in the gross margin of its glove products starting from the fourth quarter of 2025 [1] - As of January 2026, glove prices have shown a steady recovery [1] - The company is enhancing its cost competitiveness through various initiatives, including the integration of nitrile glove production capacity with Thai industrial investors, the acquisition of Hongda Thermal Power to address energy supply shortages, and the establishment of a self-owned power plant at its Weifang factory [1]

Core Viewpoint - The company, Bluestar Medical, announced significant advancements in its product development, specifically the SoniCracker™-CL catheter and the Lithonic™ system, which are expected to enhance its market position in the medical device industry [1] Group 1: Product Development - The SoniCracker™-CL, a disposable intravascular shockwave catheter, is set to receive the medical device registration certificate from NMPA in 2024 [1] - The Lithonic™ intravascular shockwave therapy system is anticipated to obtain CE certification in January 2026, enabling the company to initiate overseas sales shortly thereafter [1] - The company expects rapid market penetration and sales growth for the Lithonic™ system following its certification [1]